Abstract: The present invention provides a pharmaceutical composition for use in treating cognitive decline. The pharmaceutical composition of the present invention comprises an antagonist of an AMPA receptor. The present invention also provides pharmaceutical compositions for use in treating a disease or condition associated with NMDA insensitivity in an NMDA-insensitive subject. The present invention can be useful, for example, in a subject in which intracellular calcium influx by stimulation with NMDA and glycine is inhibited in an NMDA receptor from which inhibition of activation by Mg ions has been released. The present invention further provides a pharmaceutical composition for use in treating overweight and obesity.

Abstract: It is an object of the present invention to provide an antibody that binds to CADM1 expressed on a cell, wherein the antibody alone is capable of inducing internalization of the antibody and the CADM1 into the cell. Specifically, the present invention relates to an antibody binding to CADM1 (Cell adhesion molecule 1), in which the antibody binds to CADM1 on the surface of a cell and induces internalization of the antibody and the CADM1 into the cell, or an antigen-binding fragment thereof.

Abstract: Provided is a metabolism improving agent that contains, for example, an alkalizing agent such as an acidosis improving agent or a urinary alkalizing agent as an active ingredient, and has actions such as improvement of insulin resistance, improvement of pituitary and adrenal functions, and reduction of visceral fat accumulation.

Abstract: Adipose-derived stem cells are isolated and extracted from an adipose tissue without using collagenase. An adipose tissue is covered with a nonwoven fabric sheet having sufficient interfiber space and pressed by an appropriate force. Thus, the adipose tissue infiltrates among fibers of the nonwoven fabric and then comes into contact with fibers surrounding the same. By immersing the nonwoven fabric as such in a culture medium, a number of adipose-derived stem cells are allowed to crawl out from the adipose tissue and then adhered to the fiber surface.

Abstract: A plasma sterilization apparatus includes a voltage-applying unit that applies a voltage to a sterilization target having conductivity; a pair of electrodes that apply, in a discharged state, the voltage applied by the voltage-applying unit to the sterilization target via a dielectric; and a position changing unit that changes a relative position between the pair of electrodes and the sterilization target.

Abstract: A method of treating fatty liver comprising administering an effective amount of a plant belonging to a genus Cirsium to a patient in need of the treatment.

Abstract: A solar light (heat) absorption material which has an excellent solar light (heat) absorbing ability and a simple structure, and may be used as a low-cost and high-performance heat absorption/accumulation material. Also, a solar light (heat) absorption/control building component including the solar light (heat) absorption material that allows for easy change of its solar light (heat) absorption/control ability. The material includes particles dispersed into a liquid medium having a specific heat ranging from 0.4 to 1.4 cal/g/° C. and a melting point of 5° C. or lower. The dispersed particles have L*value of 30 or less as determined by the CIE-Lab color system (light source D65).

Abstract: The present invention provides an agent having anti-Helicobacter pylori activity that is effective for the treatment, prevention or improvement of diseases associated with Helicobacter pylori and contains as an active ingredient thereof an extract of a plant belonging to the Labiatae family. The agent having anti-Helicobacter pylori activity of the present invention has superior heat stability and allows the obtaining of elimination effects in a short period of time.

Abstract: The invention provides a composition for prevention or treatment of a disease associated with the production of an autoantibody. Specifically, it provides a composition for the prevention or treatment of a disease associated with the production of an autoantibody, which comprise royal jelly as an active ingredient.

Abstract: An objective of the invention is to provide a drug delivery vehicle capable of allowing a vaccine or adjuvant to reach a target cell or tissue efficiently while being capable of improving the immunogenicity of the vaccine or capable of enhancing the immunostimulating effect of the adjuvant as well as a vaccine or adjuvant utilizing the same. Said drug delivery vehicle contains a multimeric protein having a coiled coil structure and a ligand molecule to a receptor of an immune cell.

Abstract: A plasma generator in which the variation of the impedance in the cavity before and after plasma is ignited is less and hardly affected by the shape of the cavity, and the ignitability of the plasma is improved and a method of generating plasma using the plasma generator are provided. The plasma generator comprises a nonconductive gas flow pipe (1) for introducing a gas (9) for generating plasma and discharging it into the atmosphere and a conductive antenna pipe (2) surrounding the gas flow pipe. A microwave (7) is applied to the antenna pipe to change the gas in the gas flow pipe into plasma. The plasma generator is characterized in that a slit (3) with a predetermined length is formed in the antenna pipe (2) along the axial direction of the gas flow pipe. Preferably, the plasma generator is characterized in that the length of the slit is an integral multiple of the half-wave length of the applied microwave.

Abstract: An objective of the invention is to provide a drug delivery vehicle capable of allowing a vaccine or adjuvant to reach a target cell or tissue efficiently while being capable of improving the immunogenicity of the vaccine or capable of enhancing the immunostimulating effect of the adjuvant as well as a vaccine or adjuvant utilizing the same. Said drug delivery vehicle contains a multimeric protein having a coiled coil structure and a ligand molecule to a receptor of an immune cell.

Abstract: It is intended to provide a sterilizer, which aim is at efficiently sterilizing a subject such as a container by using active oxygen generated with the use of plasma, and a sterilization method using the same. In particular, it is intended to develop a technique for stably generating active oxygen with the use of plasma and thus provide a sterilizer, which enables, if necessary, stable plasma formation and active oxygen generation in the atmosphere and can inhibit thermal damages caused by the plasma on a subject to be sterilized, and a sterilization method using the same.

Abstract: A plasma generator in which the variation of the impedance in the cavity before and after plasma is ignited is less and hardly affected by the shape of the cavity, and the ignitability of the plasma is improved and a method of generating plasma using the plasma generator are provided. The plasma generator comprises a nonconductive gas flow pipe (1) for introducing a gas (9) for generating plasma and discharging it into the atmosphere and a conductive antenna pipe (2) surrounding the gas flow pipe. A microwave (7) is applied to the antenna pipe to change the gas in the gas flow pipe into plasma. The plasma generator is characterized in that a slit (3) with a predetermined length is formed in the antenna pipe (2) along the axial direction of the gas flow pipe. Preferably, the plasma generator is characterized in that the length of the slit is an integral multiple of the half-wave length of the applied microwave.

Abstract: A heteropentamer composed of a fusion monomer (32) comprising a fusion protein of an antigenic amino acid sequence and an amino acid sequence of a monomer of a mucous membrane-binding protein and a nonfusion monomer (20) of an amino acid sequence of a monomer of a mucous membrane-binding protein. A homopentamer composed of a fusion monomer including a fusion protein of an antigen derived from an envelope protein of Japanese encephalitis virus and an amino acid sequence of a monomer of a mucous membrane-binding protein. These heteropentamer and the homopentamer can be used as a vaccine.

Abstract: A leishmaniasis preventing and/or treating agent having 2-deoxy-2-[(3S)-(9-phenylnonanoyloxy)tetradecanoyl]amino-3-O-(9-phenylnonanoyl)-4-O-sulfo-&agr;-D-glucopyranose represented by a formula (I) or a non-toxic salt thereof as an effective ingredient. 2-deoxy-2-[(3S)-(9-phenylnonanoyloxy)tetradecanoyl]amino-3-O-(9-phenylnomanoyl)-4-O-sulfo-&agr;-D-glucopyranose represented by a formula (I) or a non-toxic salts effectively functions to prevent and/or treat leishmaniasis, and is a highly safe compound.